Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anacor Pharmaceuticals has completed patient enrollment in the first of two Phase 3 trials of a topical anti-fungal product, Tavaborole (AN2690), used in the treatment of onychomycosis.
Subscribe to our email newsletter
The Phase 3 trial includes two double-blind vehicle-controlled trials with two-to-one randomisation between Tavaborole and vehicle (the topical formulation without the active ingredient).
Anacor Pharmaceuticals CEO David Perry said they hope that Tavaborole can provide improved standards of care for onychomycosis, including safety and efficacy.
"We have completed enrollment of approximately 600 patients in the first of two Phase 3 trials for Tavaborole. We expect to complete enrollment in our second Phase 3 trial by year-end 2011," Perry added.
The company is likely to present the results by the end of 2012.